The design of infant immunization schedules requires an understanding of the factors that determine the immune response to each vaccine antigen.
I
t is difficult to overstate the global effect of routine infant immunization on reducing morbidity and mortality from infectious diseases. However, the design of immunogenic schedules for routine immunization is increasingly challenging owing to the variety of vaccines in use, the use of prenatal immunization programs for some pathogens, and differences in the epidemiology of infections. A detailed understanding of the variables that influence immunogenicity is therefore of great importance. Two key factors that can affect the immunogenicity of infant vaccines are (1) the residual concentration of maternal placentally transferred antigenspecific antibodies at the time of immunization and (2) the age at which immunizations are given.
Maternal antibodies are transferred to an infant via the placenta during the third trimester of pregnancy and are important in providing protection against infection during the first months of life. [1] [2] [3] The amount of antibody transferred from mother to infant depends primarily on the gestational age at birth, placental function, and serum antibody concentration in the mother. 4, 5 Following birth, the concentration of maternally derived antibodies declines over weeks to months while infant immune competence gradually increases. 1 High concentrations of maternally acquired antibodies have been shown to inhibit the immune response to infant vaccination against some antigens. 4, [6] [7] [8] [9] [10] [11] [12] However, owing to the small size of most studies, there is inconsistent evidence on the extent of this inhibition and a lack of consensus regarding which antigens or vaccines are affected. In addition, the magnitude of the infant's antibody response to vaccination is affected by the age of the infant, with older infants generally responding better to vaccines than younger infants. 1, 13, 14 Since transplacentally acquired antibody decays over time, the interference with vaccine responses reduces with age and observed age effects on vaccine responses may therefore be due to reduced maternal antibody interference. Previous studies have not been able to separate the influence of these interrelated components on the infant immune response, leading to the observation that, "multivariate analyses on a large number of infants are required to identify the main determinants of vaccine antibody responses." 15(p32) Reduced response to infant vaccination is important in the context of prenatal immunization programs. Currently, vaccination with a pertussis-containing vaccine in the second or third trimester of pregnancy is recommended in many countries. [16] [17] [18] [19] [20] Maternal immunization with diphtheria-tetanus-pertussispolio vaccine during pregnancy effectively protects infants against pertussis disease in the first few months of life. 21, 22 However, subsequent diminished responses to infant vaccination may leave children more susceptible to disease in later infancy and increase the transmission rates to unvaccinated cohorts. 12 In this investigation, we combined serologic data from multiple randomized clinical trials to create a large cohort of infants vaccinated at various ages under different schedules from whom serum antibody concentrations were measured both before and after vaccination. We conducted a meta-analysis and calculated the effects of preexisting antibody and age at vaccination on antibody responses to priming and booster vaccines. From these results, we investigated to what extent a delay in vaccination would offset the maternal inhibition of infant antibody responses and whether maternal antibody inhibition was less pronounced in schedules with a wider spacing of doses.
Methods

Data Source
Fully deidentified data from clinical trials were available through Clinical Study Data Request (https://clinicalstudydatarequest .com/). Data were obtained as part of a wider series of studies on immune responses to infant vaccination. 23 Studies included in the present report are a subset of immunogenicity trials in which antibody concentrations were measured prior to the first dose of vaccine. All trials from which these data were obtained were sponsored by GlaxoSmithKline and assays were conducted in the GlaxoSmithKline central laboratory. The outcomes were antigen-specific IgG concentrations at 1 month after the third priming dose (approximate age, 5-7 months) and both before and 1 month after the booster vaccination.
Statistical Analysis
Antibody concentrations were log 2 -transformed and analyzed using mixed-effects models for each antigen and time point separately. Infants were included if antibody concentrations were available at both the prevaccination visit (maternal antibody) and the postvaccination time point. Children who received a placebo or no vaccine were excluded. Some studies were conducted in multiple countries. Instead of an analysis grouped at the study level, a country cohort variable was created that was unique to countries within studies. Maternal antibody was included in models as a continuous covariate (model 1) and, for comparison, sensitivity analyses were conducted with maternal antibody as a binary variable (above the lower limit of assay detection or not; model 2). Mixed-effects models contained country cohort-level random intercepts and were adjusted for age at first vaccination (months). Adjustment for additional factors known to influence antibody responses (eg, sex, vaccine received, and the scheduled spacing of doses) were included in models to account for their influence; however, coefficients from these parameters are not presented.
The antilog (2 x ) of the coefficients from models and their 95% CIs are presented as geometric mean ratios (GMRs). These ratios are interpreted as the relative increase (fold-rise) in antibody response that is associated with a 1-unit change in the given covariate. For age at vaccination, the GMR is the relative increase in antibody response for a 1-month older child. For log 2 -transformed maternal antibody concentrations, the GMR is the relative increase in antibody response associated with a doubling in maternal antibody concentrations. Further details of statistical analyses are contained in the eMethods in the Supplement. A list of all assays and assay thresholds is included in eTable 1 in the Supplement.
Results
Antibody data were available for 21 antigens from 19 child cohorts (7630 infants) from 32 studies in 17 countries (eTables 2 and 3 in the Supplement). Children from different studies varied in age at the time of enrollment, resulting in a total age range of 5 to 20 weeks, with mean (SD) age at baseline 9.0 (2.3) weeks; 3906 (51.2%) of the infants were boys. Children received vaccines according to 1 of 4 schedules: 6, 10, and 14 weeks; 2, 3, and 4 months; 2, 4, and 6 months, or 3, 4, and 5 months. For acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin), 2-fold higher preexisting antibody was associated with 11% lower postvaccination antibody for pertussis toxoid (GMR, 0.89; 95% CI, 0.87-0.90) and filamentous hemagglutinin (GMR, 0,89; 95% CI, 0.88-0.90) and 22% lower pertactin antibody (GMR, 0.78; 95% CI, 0.77-0.80).
For tetanus and diphtheria, these estimates were 13% (GMR, 0.87; 95% CI, 0.86-0.88) and 24% (GMR, 0.76; 95% CI, 0.74-0.77), respectively ( Figure 1 ; eTable 4 in the Supplement).
In the binary analysis, infants who were seropositive for pertussis antigens had 23% lower postvaccination pertussis toxoid antibody, 27% lower filamentous hemagglutinin antibody, and 50% lower pertactin antibody. For both tetanus and diphtheria, seropositive infants had 53% lower postvaccine antibodies (eFigure 1 and eTable 4 in the Supplement).
Effect of Preexisting Antibody to Carrier Proteins
In an analysis of a subset of participants who received pneumococcal conjugate vaccines (PCV7, n = 466 and PCV10, n = 1457), the effect of preexisting antibody to related carrier proteins (diphtheria and tetanus) was assessed simultaneously, while also adjusting for preexisting pneumococcal antibodies. For PCV7 vaccine, conjugated to diphtheria crossreacting material, preexisting diphtheria antibodies were associated with reduced responses to serotypes 4 (GMR, 0.93; 95% CI, 0.87-0.98), 6B (GMR, 0.88; 95% CI, 0.80-0.98), and 9V (GMR, 0.91; 95% CI, 0.86-0.97) pneumococcal polysaccharides, whereas preexisting tetanus antibodies had no effect. In contrast, in PCV10 vaccine recipients, preexisting diphtheria antibodies were associated only with reduced responses to serotype 19F antibodies (the only serotype conjugated to diphtheria protein) (GMR, 0.84; 95% CI, 0.80-0.89), whereas preexisting tetanus antibodies affected both serotypes 18C and 19F pneumococcal antibodies (18C conjugated to tetanus protein) (GMR, 0.94; 95% CI, 0.91-0.99; and 0.92; 95% CI, 0.88-0.96, respectively) (eTable 5 in the Supplement).
Similarly, in recipients of Haemophilus influenzae type b vaccine conjugated to tetanus toxoid, a small degree of inhibition of PRP responses was associated with preexisting PRP antibodies (GMR, 0.96; 95% CI, 0.93-0.99) and preexisting tetanus antibodies (GMR, 0.97; 95% CI, 0.94-0.996). Preexisting diphtheria antibodies had no influence on PRP responses (GMR, 0.96; 95% CI, 0.94-0.99).
The Effect of Age at First Vaccination on Response to Priming Immunizations
For antibodies against 18 of the 21 antigens studied, children who were older when initially immunized had between 10% and 71% higher postvaccination antibody per additional month of age (Figure 1 ). These effects remained after adjusting for preexisting antibody. The largest effect was seen for PRP antibody, where responses were 71% higher per month (GMR, 1.71; 95% CI, 1.52-1.92). No effect of age at first vaccination was seen for capsular group C meningococcal antibodies and serotypes 14 and 23F pneumococcal antibodies ( Figure 1 and eTable 4intheSupplement, model 1).
Scheduled Spacing of Doses
Twelve studies were conducted using a 2-, 4-, and 6-month schedule, and 3 studies used a 2-, 3-, and 4-month schedule. When models were fitted within these subgroups separately, the effect of maternal antibodies in terms of proportionate reduction in postvaccination responses was similar for both schedules ( Figure 2 ). 
Persistence of Antibody at Prebooster Time Points
A subset of 12 trials administered booster vaccinations between ages 12 and 24 months. At prebooster time points, lower responses associated with preexisting maternal antibodies at the time of the first vaccination were still evident for 16 of the 20 antigens. Age at first vaccination also had a significant effect on antibody levels prior to booster vaccination for all antigens except tetanus and serotype 23F pneumococcal antibodies (eFigure 2 and eTable 6 in the Supplement).
Antibody Concentration After Booster Vaccines
The concentration of maternal antibodies prior to the first vaccination was associated with reduced responses to booster doses for diphtheria, pertussis antigens, inactivated polio, and 5 of 10 (50%) serotypes of pneumococcus ( Figure 3 and Figure 4 ; and eTable 7 in the Supplement). For diphtheria, the pertussis antigens pertussis toxoid and filamentous hemagglutinin, inactivated polio type 3, and 5 of 10 (50%) serotypes of pneumococcus, the age at first vaccination had a persistent positive effect on postbooster antibody levels. The largest differences were observed for diphtheria, pneumococcal serotypes 5 and 18C, and polio type 3, where antibody levels were between 28% and 48% higher for each month of delay in the initial vaccination. In contrast, the age at booster vaccination was associated with higher antibody concentrations only for tetanus and PRP antibodies (9% and 15% increase per month, respectively).
Overall Effect of Delaying Vaccination
A delay in age at the first immunization resulted in a combined beneficial effect on immunogenicity due to (1) a reduction in maternal antibody interference associated with antibody decay and (2) an increase in infant age. Assuming a half-life of 26 days for pertussis toxoid maternal antibodies, the total benefit for acellular pertussis was a 1.06-fold increase (GMR, 1.06; sensitivity range, 1.05-1.06, using half- lives of 29 to 43 days) in pertussis toxoid antibody concentrations per week of delay in the first infant dose of vaccine. The number of weeks' delay required to offset a 2-to 5-fold increase in infant levels of maternal pertussis antibodies due to prenatal immunization was between 2.2 and 5.04 weeks. For diphtheria and tetanus, these estimates were 2.6 to 5.9 and 1.7 to 3.9, respectively ( Figure 5 ).
Discussion
Our analysis of the serum of more than 7600 infants from 17 countries surmounts the problem of insufficient statistical power inherent in previous attempts to investigate maternal antibody interference with infant vaccine immunogenicity, which has led to inconsistent and/or nonsignificant findings. Our analysis comprehensively models the effects of maternal antibody inhibition and infant age at vaccination on the majority of vaccine antigens contained in current global infant immunization programs and reveals that, for almost all antigens, transplacental antibody inhibits the antibody response to priming vaccinations and these effects are not diminished by administration of a booster dose. These analyses further reveal the benefit of infants being older when first immunized, an association that remains after adjusting for waning maternal antibody levels.
In contrast to previous reports, 10 the effects of maternal antibodies and the infant's age when first immunized are not only seen in response to a priming series of vaccines, but continue to affect antibody responses to booster vaccinations at ages 12 to 24 months for many antigens. This finding suggests the importance of the quality of the immune response to the first dose of antigen, regardless of subsequent doses.
The influence of maternal antibodies on measles vaccine immunogenicity has been widely studied to determine the optimal age for vaccination. Younger infants (approximately 6 months) have higher maternal antibody concentrations and lower antibody responses to measles vaccine compared with older infants (approximately 9-12 months), but also produce lower neutralizing antibody responses in the absence of maternally derived measles antibodies. 42 In contrast, there is little consensus in the medical literature regarding the potential for, extent of, or clinical implications of maternal antibody interference with vaccines received in early infancy. O'Brien et al 10 reported maternal antibody interference with priming doses of PCV7 in infants, and Englund et al 8 reported inhibition for whole cell pertussis vaccine but observed no association between maternal antibody to pertussis toxoid and infant responses to 13 different acellular pertussis vaccines in a combined, yet unadjusted, analysis. Other studies are limited in size or incorporate only historical control methods prone to bias. In a small study of 36 infants, Jones et al 43 showed that high levels of maternal antibody inhibited responses to pneumococcal conjugate vaccine as well as to tetanus toxoid, but no effect was seen against acellular pertussis toxoid or H influenzae type b, and other small studies have failed to find significant effects. [44] [45] [46] Our analysis reveals that, not only are infant responses inhibited by maternal antibody to the same antigen, but responses to conjugate vaccines in infancy are also affected by antibody to related carrier proteins. 
Schedule Comparisons
Schedules with a wider spacing of doses delivered the second and third doses of vaccine after a longer interval, allowing for maternal antibody decay. In our analyses, substantial inhibition was associated with preexisting antibodies for both the 2-, 4-, and 6-month and 2-, 3-, and 4-month schedules. The interference due to maternal antibodies is thus predominantly mediated through the effect on response to the first dose of vaccine.
Policy Implications
In settings where prenatal immunization programs are well established with high coverage, maternal antibodies provide protection against pertussis for most infants in the first few months of life. 21 In such settings, a delay in administration of the first vaccination would increase responses to infant vaccination if vaccine coverage is high, and the current schedule already includes an early first dose (≤2 months). We calculated the magnitude of the expected total increase in vaccine antibody due to a delay in vaccination by combining model parameters with the half-life of maternal antibodies. The magnitude of the increase in maternal antibody concentrations in infants due to prenatal immunization programs has not been well established, but estimates from a small randomized trial 45 and nonrandomized studies 47, 48 suggest that, for pertussis, between 2-fold and 5-fold higher antibody concentrations may be induced. Our models show that the inhibitory effect of a 2-fold to 5-fold increase in maternal antibody concentrations in infants can be offset by a delay in vaccination of between 2.2 and 5.0 weeks-time periods that are short enough to make delayedstart vaccination a feasible option. Since current prenatal immunization programs use diphtheria and tetanus-containing vaccines, a delay in immunization may improve responses to other vaccines containing these carrier proteins.
Decisions regarding the timing of infant vaccinations need to consider the length of time during which direct protection afforded by prenatal immunization is maintained in infants, an area in which there are currently few data. Infant immunization programs need to consider the level of disease risk in early infancy and the level of coverage of prenatal programs, as well as balance the complex interaction between the direct protection afforded the infant early in life by maternal vaccination, against the increased risk of disease later in infancy as a result of reduced immunogenicity, and the increase risk of disease in the population due to reduced indirect effects. This tradeoff is minimized if the vaccine schedule can be improved to increase infant responses to vaccination.
Limitations
The studies included herein were conducted in the absence of prenatal vaccination programs. The effects of antibodies induced by natural exposure and those induced by vaccination during pregnancy may differ. In addition, preexisting antibodies in the infant may be due to exposure of the infant to circulating pathogens, such as pneumococcal or pertussis antigens, in the first few months of life rather than being entirely due to maternal antibody transmission. These models may, therefore, underestimate the effect of maternal antibody interference for widely circulating pathogens.
Conclusions
Older infants mount greater antibody responses to vaccination and maternal transplacental antibodies inhibit infant responses. These effects are observed for both priming and booster vaccine doses and occur for almost all antigens present in global immunization programs. Antibody responses to conjugate vaccines are not only affected by interference from preexisting antibodies to the polysaccharide antigen, but also from antibodies associated with carrier proteins. Therefore, prenatal immunization programs containing multicomponent vaccines have the potential to interfere with the immunogenicity of current immunization programs. However, the clinical relevance in terms of potential reductions in disease due to maternal antibody interference on infant vaccine immunogenicity is not known.
Decisions regarding the design of infant immunization schedules are increasingly complex owing to greater numbers of vaccine antigens, prenatal immunization programs, and the addition of booster doses of vaccines throughout childhood and adolescence. These data on key factors that influence the immune response will help in the planning of immunization schedules and provide important factors for evaluating their cost-effectiveness. Role of the Funder/Sponsor: The funder had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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Supplementary Online Content
eMethods. Secondary and Subgroup Analyses
In a secondary analysis, the effect of maternal antibody to related carrier proteins on antibody responses to pneumococcal and Hib vaccines was conducted using a similar model to model 1 above. Maternal antibody to the homologous antigen (pneumococcus or Hib) was included in the model along with the maternal antibody concentration for the carrier proteins (diphtheria and tetanus) to assess the effect of pre-existing antibody to related carrier proteins whilst simultaneously adjusting for the effect of pre-existing antibody to the homologous antigen.
Subgroup analyses were conducted for subsets of trials in which vaccines were administered at 2, 4, and 6 months, or 2, 3, and 4 months of age. These models were unadjusted for the schedule of administration.
In each model, fixed effects were removed if a factor had only one level, or if there were too few levels for model stability (e.g. if all included studies administered the same vaccine type or the same schedule).
Effect of delaying first vaccination
To model the effect of delaying vaccination on infant responses to a priming series of vaccinations, the antibody half-life was used to estimate the extent of decay in maternal antibody concentrations per week, and the subsequent reduction in maternal antibody interference. The impact of reduced maternal antibody interference was combined with the effect of increased responses due to being older when first immunised to estimate the total benefit in increased responses which could be expected with each week of delay in vaccination.
The number of weeks delay in infant vaccination required to offset the interference due to increased infant levels of maternal antibody was therefore calculated as follows; Thus to estimate the number of weeks (w) delay in vaccination required to offset the effect of a 5-fold increase in pertussis antibody concentration in infants due to a prenatal vaccination programme, assuming log 2 -transformed maternal antibody decays linearly over time, we calculate: As antibody half-lives are not well characterised in the published literature, we calculated estimates based on half-lives of 7 days longer and 7 days shorter to give a range of estimates as shown in Figure 4 . 
